Loading...
Please wait, while we are loading the content...
Similar Documents
The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis.
| Content Provider | Europe PMC |
|---|---|
| Author | Chang, Young Jeong, Soung Won Jang, Jae Young Eun, Hyuksoo Lee, Young‑Sun Song, Do Seon Yu, Su Jong Lee, Sae Hwan Kim, Won Lee, Hyun Woong Kim, Sang Gyune Ryu, Seongho Park, Suyeon |
| Copyright Year | 2022 |
| Abstract | Background/Aim New biomarkers are urgently needed to aid in the diagnosis of early stage hepatocellular carcinoma (HCC). We performed a meta-analysis on the diagnostic utility of circulating tumor DNA (ctDNA) levels in patients with hepatitis B virus-induced HCC. Methods We retrieved relevant articles from PubMed, Embase, and the Cochrane Library up to February 8, 2022. Two subgroups were defined; one subset of studies analyzed the ctDNA methylation status, and the other subset combined tumor markers and ctDNA assays. Pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (AUC) were analyzed. Results Nine articles including 2,161 participants were included. The overall SEN and SPE were 0.705 (95% confidence interval [CI], 0.629-0.771) and 0.833 (95% CI, 0.769-0.882), respectively. The DOR, PLR, and NLR were 11.759 (95% CI, 7.982-17.322), 4.285 (95% CI, 3.098-5.925), and 0.336 (0.301-0.366), respectively. The ctDNA assay subset exhibited an AUC of 0.835. The AUC of the combined tumor marker and ctDNA assay was 0.848, with an SEN of 0.761 (95% CI, 0.659-0.839) and an SPE of 0.828 (95% CI, 0.692-0.911). Conclusions Circulating tumor DNA has promising diagnostic potential for HCC. It can serve as an auxiliary tool for HCC screening and detection, especially when combined with tumor markers. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10035733&blobtype=pdf |
| ISSN | 22888128 |
| Volume Number | 22 |
| DOI | 10.17998/jlc.2022.09.19 |
| PubMed Central reference number | PMC10035733 |
| Issue Number | 2 |
| PubMed reference number | 37383408 |
| Journal | Journal of Liver Cancer [J Liver Cancer] |
| e-ISSN | 23835001 |
| Language | English |
| Publisher | The Korean Liver Cancer Association |
| Publisher Date | 2022-09-29 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2022 The Korean Liver Cancer Association |
| Subject Keyword | Carcinoma, hepatocellular Circulating tumor DNA Biomarkers Diagnosis |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
